We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Prothena collaborates with scientists with expertise in our areas of interest to test and characterize our therapeutic antibody candidates.